Virtual Program

Our 2-day virtual summit, to be held 20-21 September, features thought-provoking plenary sessions, topical presentations and discussions, educational symposia and speakers from a diverse array of backgrounds excited to share with you a wealth of ideas, experiences, and perspectives on the latest HEOR topics in Asia Pacific. 

Special Bonus: Registration includes extended access to all session playback recordings through 21 October 2022.

Note: Times shown within the program are in Korean Standard Time (KST). The Summit will be presented in English without translation.

Can We Do Better for Health Technology Assessors & Patients? How to Overcome “Mistrust” in Digital Technology for Asia Pacific

Speaker(s)

Moderator: Kenneth Kwing Chin Lee, MPhil, PhD, School of Pharmacy, Monash University Malaysia, Petaling Jaya, Malaysia
Panelists: Shu Chuen Li, MApplSc, MBA, PhD, School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan, NSW, Australia; Izzuna Mudla Mohamed Ghazali, MBBS, MPH, MPH, Medical Development Division Ministry of Health Malaysia, Malaysian Health Technology Assessment Section (MaHTAS), Putrajaya, Malaysia; Gurmit Sandhu, BPharm (Hons), MBA, MPH, Gurmit Sandhu Consulting GmbH, Basel, BS, Switzerland

Presentation Documents

ISSUE:

Digital health technologies (DHTs) offer potential value to personalized care for cancer patients. However, reimbursement, funding, and adoption of DHTs depend on the healthcare system priorities, infrastructure, and level of trust in DHT by payers/funders, HCPs, and patients. Several value aspects determine trust. We focus on the value assessment. While in high-income countries, the payer level of trust is often determined by applying sophisticated value frameworks from pharmaceuticals to assess the DHTs’ value. In low-middle income countries (LMCIs), the diversity in the socio-economic status and healthcare systems imposes challenges to applying these frameworks similarly. This provides opportunities for developing new fit-for-purpose frameworks for these healthcare systems. The session discusses trust- and value drivers of DHTs for HTA, funders, and patients in Asia-pacific countries. Case studies will elucidate their different perspectives. We aim to get feedback from the Asia Pacific ISPOR community on the relevant value drivers and acceptable level of evidence to invest in trustworthy DHTs.

OVERVIEW:

An interactive session will address the following questions:

  1. What drives funding and adoption of DHTs in LMICs from a public and private perspective accounting for DHT use acceleration during the COVID-19-pandemic, the rapidness of emerging new technologies, and the IoT status?
  2. What is the patients’ role in the value assessment and funding of DHTs?
  3. What are the biggest hurdles for healthcare systems to fund DHTs?
  4. How can we measure patient-relevant outcomes and cost in LMICs? What is the role of RWE?
Participants from public and private payers, HTA agencies, policymakers, medical technology manufacturers, patient advocacy representatives, and healthcare providers will benefit from attending this session. They will better understand the critical aspects of the value assessment of DHTs in LMCIs. The collected feedback will inform the development of a value framework to inform reimbursement and funding decision-making in LMCIs.

Code

IP15